WO2021066248A1 - Composition comprenant un exosome dérivé de nid d'océanite à queue fourchue en tant que principe actif pour améliorer une condition cutanée - Google Patents

Composition comprenant un exosome dérivé de nid d'océanite à queue fourchue en tant que principe actif pour améliorer une condition cutanée Download PDF

Info

Publication number
WO2021066248A1
WO2021066248A1 PCT/KR2019/015996 KR2019015996W WO2021066248A1 WO 2021066248 A1 WO2021066248 A1 WO 2021066248A1 KR 2019015996 W KR2019015996 W KR 2019015996W WO 2021066248 A1 WO2021066248 A1 WO 2021066248A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
nest
skin
present
improving skin
Prior art date
Application number
PCT/KR2019/015996
Other languages
English (en)
Korean (ko)
Inventor
박설웅
황은선
양정은
Original Assignee
(주)에스디생명공학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)에스디생명공학 filed Critical (주)에스디생명공학
Publication of WO2021066248A1 publication Critical patent/WO2021066248A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/204—Animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to a composition for improving skin condition comprising exosomes derived from bird's nest as an active ingredient, and more specifically, containing exosomes derived from bird's nest as an active ingredient, improved skin wrinkles, anti-atopic It relates to a composition for improving skin conditions having anti-inflammatory, skin moisturizing, skin whitening, and skin regeneration activity.
  • Most animal cells can secrete extracellular vesicles of various sizes and components, which are found in all biological fluids, including blood, urine, saliva, and cell culture. .
  • the endoplasmic reticulum is a membrane-structured vesicle having a size from about 20 nm in diameter to about 5 ⁇ m in diameter as large as it is, and is heterogeneous in its size and composition, exosomes (about 30-100 nm), ectosomes , Microvesicle (about 100 ⁇ 1,000 nm), microparticles (microparticle), apoptosis (apoptotic body, about 1 ⁇ 5 ⁇ m), etc. are classified.
  • micro vesicles are membrane vesicles having an irregular shape of about 100 to 1,000 nm, separated toward the outside of the plasma membrane, and having a marker including integrin, selectin, CD40 ligand, and phospholipids including phosphatidylserine. It is known to be.
  • exosomes are the smallest membrane vesicles having a cup shape of about 30 to 100 nm ( ⁇ 200 nm), originating from late endosomes and separated into the inside of endosomes, generally CD63, tetraspanin of CD9, It is known to have lipids including markers including TSG101, ESCRT, and the like, cholesterol, sphingomyelin, ceramide, and phosphatidylserine.
  • Geumsayeon a type of sea swallow that lives on mountains and cliffs around the sea in southern China, Malay Peninsula, Java, Sumatra, and other countries in Southeast Asia, creates a bird's nest by spitting sticky secretions from the salivary glands in the throat.
  • the saliva secreted from the salivary glands of Geumsayeon developed during the spawning period hardens, such as feathers, and the nest is made over about a month.
  • the bird's nest is introduced in the Bonchogangmok, saying, "It moisturizes the skin and is beneficial to the blood.”
  • the bird's nest is excellent in its rejuvenating effect, and the Empress of China mixed the bird's nest with pearl powder to maintain her beauty and youthfulness, and used it for skin care.
  • the bird's nest contains protein that nourishes the skin, so it makes dry skin more smooth and contains vitamin C, vitamin E, arbutin, and collagen that give elasticity to tired skin.
  • Proteoglycan the main ingredient in the bird's nest, plays a big role in binding or supporting individual cells such as the whole body, skin, and organs, and has an excellent regeneration effect on the skin, preventing loss of moisture content and improving skin aging. Can play a major role in
  • Swallow nests are harvested under strict monitoring so that only authorized harvesters are allowed to collect them locally, and the annual harvesting amount is also limited, and they are used as very expensive food ingredients.
  • efficacy of the extract extracted from the bird's nest antiviral and whitening effects are known.
  • Patent Application No. 10-2015-0053874'Functional cosmetic composition containing a bird's nest extract as an active ingredient' can be used in a functional cosmetic composition because the bird's nest, sea cucumber extract, and caviar extract have effects such as skin whitening and wrinkle improvement.
  • the effect is not sufficient, so there is a disadvantage that the economical efficiency is deteriorated.
  • the present inventors have made extensive research efforts to further improve the functionality of the expensive functional material, the bird's nest, and to enhance its utilization value.
  • the exosome ingredient derived from the bird's nest has an excellent effect on improving skin wrinkles and atopic dermatitis.
  • it is effective in promoting inflammation, skin whitening, skin moisturizing, and regeneration of damaged skin, it was confirmed that it has an excellent effect in improving the skin condition, and this invention was completed.
  • the main object of the present invention is to prevent or improve skin wrinkles and atopic dermatitis, anti-inflammatory, skin whitening, skin moisturizing, and excellent effect in promoting the regeneration of damaged skin, the exosomes derived from the bird's nest It is to provide a composition for improving skin conditions, including as an active ingredient.
  • the present invention provides a composition for improving skin conditions, including an exosome derived from a bird's nest as an active ingredient.
  • the present inventors have made extensive research efforts to further increase the functionality for improving the skin condition of the expensive bird's nest to increase the usability of the material, and as a result, the exosome ingredient derived from the bird's nest has an excellent effect on improving skin wrinkles and atopic dermatitis, It is effective in promoting anti-inflammatory, skin whitening, skin moisturizing, and regeneration of damaged skin, and it was confirmed that it has an excellent effect in improving the skin condition.
  • the term "Swallow's Nest” in the present invention means a nest built by Collocalia fuciphaga, which is a kind of sea swallow, and the sea swallow's nest is built by woven seaweed and fish fins as the main material with the secretions secreted from the salivary glands. .
  • Geumsayeon makes a nest by secreting food that has not yet been digested when it is nested on a coastal cliff, and the bird's nest at this time is called white and shiny, so it is also called baekyeon.
  • the term'exosome' refers to a follicle having a diameter of approximately 200 to 1000 nm of a membrane structure separated from the nest, and refers to a follicle that is released into the extracellular environment due to the fusion of the polycyst and the plasma membrane. .
  • the exosomes are either naturally secreted or artificially secreted.
  • the exosome component derived from the bird's nest of the present invention is distributed in a size of 270 to 800 nm (see Fig. 1), and is characterized by containing marker proteins of human-derived exosome markers CD9, CD63, and CD81 (Fig. 2).
  • the term “improving skin condition” prevents and improves skin wrinkles, improves symptoms of atopic dermatitis and inflammatory skin disease, reduces the total amount of melanin pigment to exhibit a whitening effect, and replenishes moisture to the skin, It is meant to include all things that promote the regeneration of skin tissues or skin cells.
  • the composition for improving skin condition of the present invention, is characterized in that it exhibits an activity of preventing or improving skin wrinkles by inhibiting the generation of skin wrinkles through inhibition of the expression of MMP-1 protein.
  • skin wrinkles refers to fine lines caused by deterioration of the skin, and may be caused by genes, a decrease in collagen present in the skin dermis, an external environment, and the like.
  • prevention or improvement of skin wrinkles refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating wrinkles that have already been generated.
  • exosomes derived from sea swallow nest can be effectively used for preventing and improving skin wrinkles by effectively inhibiting the production of MMP-1 protein, which causes wrinkles (see FIG. 3).
  • the composition for improving skin condition of the present invention is characterized in that it exhibits therapeutic and prophylactic activity for atopic dermatitis through inhibition of expression of TARC (Thymus and activation-regulated chemokine) gene.
  • atopic dermatitis is a chronic and recurrent inflammatory skin disease and refers to a disease accompanied by itching (itching), dry skin, and characteristic eczema.
  • Atopic dermatitis acute lesions are characterized by a significant increase in serum immunoglobulin E (IgE).
  • IgE serum immunoglobulin E
  • histopathological changes in the lesion and sensory evaluation for dermatitis lesions are performed to diagnose and severity of atopic dermatitis. It is also judged.
  • prevention of atopic dermatitis refers to all actions of inhibiting or delaying the onset of atopic dermatitis by administration of the composition of the present invention
  • treatment of atopic dermatitis refers to the composition of the present invention. It refers to any action in which the symptoms caused by atopic dermatitis are improved or beneficially changed.
  • the generation of the TARC protein overexpressed by TNF-a and IFN-r was significantly inhibited by the treatment of exosomes derived from the bird's nest of the present invention (see FIG. 5).
  • the composition for improving skin condition of the present invention, is characterized in that the composition has therapeutic and prophylactic activity for inflammatory diseases through inhibition of production of nitric oxide.
  • inflammatory disease refers to a disease having inflammation as a major lesion, and in the present invention, the inflammatory disease is characterized in that it is a nitric oxide-mediated inflammatory disease.
  • the nitric oxide mediated inflammatory diseases include atopic dermatitis, psoriasis, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory collagen vascular disease, and the like.
  • treatment of an inflammatory disease refers to any action in which symptoms of an inflammatory disease are improved or benefited by administration of the composition
  • prevention of inflammatory disease refers to inhibiting or delaying the onset of inflammatory disease by administration of the composition. It means all actions that let you.
  • nitric oxide production was effectively inhibited by the treatment of exosomes derived from sea swallow nest (see FIG. 6),
  • the composition for improving skin condition of the present invention is characterized in that it exhibits skin moisturizing activity by promoting the synthesis of hyaluronic acid.
  • skin moisturizing means to increase the moisture sensation on the skin and maintain a moist state.
  • hyaluronic acid synthesis was effectively increased by treatment with exosomes derived from sea swallow nest (see FIG. 7).
  • the composition for improving skin condition of the present invention is characterized in that it exhibits skin whitening activity by inhibiting the production of melanin pigment.
  • skin whitening refers to not only brightening skin tone, but also improving skin hyperpigmentation such as spots and freckles caused by ultraviolet rays, hormones, or genetics. This whitening effect may be achieved, for example, by reducing the total amount of melanin pigment, but is not limited thereto.
  • melanin production was inhibited by treatment with exosomes derived from sea swallow nest (see FIG. 8).
  • the composition for improving skin condition of the present invention is characterized in that it exhibits skin regeneration activity.
  • skin wound' is meant to include a defect in the epidermis, dermis or subcutaneous tissue.
  • prevention or treatment of skin wounds' includes alleviation, alleviation and improvement of symptoms of skin wounds, and includes lowering the likelihood of skin wounds occurring.
  • the exosome component derived from the nest of sea swallows promotes skin regeneration in a concentration-dependent manner in skin cells, and thus can be effectively used for skin regeneration (see FIG. 9).
  • the present invention provides a cosmetic composition for improving skin condition, comprising an exosome derived from a bird's nest as an active ingredient.
  • the cosmetic composition of the present invention has an excellent effect in improving skin wrinkles and atopic dermatitis, and is effective in anti-inflammatory, skin whitening, skin moisturizing, and promoting regeneration of damaged skin. It can be usefully used as a cosmetic composition for promoting atopy, anti-inflammatory, skin whitening, skin moisturizing, and skin regeneration.
  • the cosmetic composition of the present invention includes ingredients commonly used in cosmetic compositions in addition to the exosome component derived from the bird's nest as an active ingredient, such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances. Such conventional adjuvants, and carriers.
  • the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , Oil, powder foundation, emulsion foundation, wax foundation, and may be formulated as a spray, but is not limited thereto. More specifically, it can be prepared in the form of a flexible lotion (skin), nutritional lotion (milk lotion), nutritional cream, massage cream, essential oil, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder. have.
  • the formulation of the present invention is a paste, cream, or gel
  • animal oil, vegetable oil, wax, paraffin, starch, tragacantha, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide are used as carrier components.
  • lactose When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component.
  • lactose talc
  • silica aluminum hydroxide
  • calcium silicate or polyamide powder
  • propellants such as butane or dimethyl ether.
  • a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
  • the formulation of the present invention is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Sex cellulose, aluminum metahydroxide, bentonite, agar or tragacantha, and the like
  • a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester
  • microcrystals Sex cellulose aluminum metahydroxide
  • bentonite agar or tragacantha, and the like
  • the formulation of the present invention is a surfactant containing cleansing, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters may be used.
  • the present invention provides a pharmaceutical composition for improving skin condition, comprising an exosome derived from a bird's nest as an active ingredient.
  • the pharmaceutical composition of the present invention has an excellent effect in improving skin wrinkles and atopic dermatitis, and is effective in anti-inflammatory, skin whitening, skin moisturizing, and promoting regeneration of damaged skin. It can be usefully used as a pharmaceutical composition for promoting anti-atopy, anti-inflammatory, skin whitening, skin moisturizing, and skin regeneration.
  • composition for improving skin condition including the exosomes derived from the nest of birds of the present invention as an active ingredient, may be prepared in the form of a pharmaceutically acceptable salt.
  • salts can be formed by adding an acid, for example, inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), organic carboxylic acids (such as acetic acid and trifluoroacetic acid).
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.
  • organic carboxylic acids such as acetic acid and trifluoroacetic acid.
  • Acetic acid, propionic acid maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid
  • acidic sugars glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid
  • acidic polysaccharides e.g.
  • hyaluronic acid chondroitin sulfate, Arginic acid
  • an organic sulfonic acid eg, methane, sulfonic acid, p-toluene sulfonic acid
  • a sulfonic acid sugar ester such as chondroitin sulfate
  • the pharmaceutical composition of the present invention can be administered orally or parenterally during clinical administration as a substance isolated from natural extracts without cytotoxicity, and can be used in the form of general pharmaceutical preparations.
  • the pharmaceutical composition of the present invention can actually be administered in various oral or parenteral formulations, but when formulated, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants are used. It is prepared by doing. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, liurinji, glycerogelatin, and the like may be used.
  • the pharmaceutical composition of the present invention may be used by mixing with various carriers permitted as drugs such as physiological saline or an organic solvent, and carbohydrates such as glucose, sucrose or dextran to increase stability or absorption.
  • drugs such as physiological saline or an organic solvent
  • carbohydrates such as glucose, sucrose or dextran to increase stability or absorption.
  • Antioxidants such as ascorbic acid or glutathione, chelating agents, small molecule proteins or other stabilizers may be used as pharmaceuticals.
  • the effective dose of the pharmaceutical composition of the present invention is 0.01 to 10 mg/kg, preferably 0.1 to 1 mg/kg, and may be administered once to three times a day.
  • the total effective amount of the pharmaceutical composition of the present invention can be administered to a patient in the form of a bolus or in a relatively short period of time by infusion or the like as a single dose, and multiple doses It can be administered by this long-term, fractionated treatment protocol. Since the concentration is determined by taking into account various factors such as the patient's age and health status, as well as the route of administration and the number of treatments of the drug, the effective dosage of the patient is determined. It will be possible to determine an appropriate effective dosage according to the specific use of the pharmaceutical composition.
  • the present invention provides a food composition for improving skin conditions, containing exosomes derived from bird nests as an active ingredient.
  • the exosome component derived from the bird's nest of the present invention is as described above.
  • the food composition may be used in the form of a health functional food, but is not limited thereto.
  • the food composition of the present invention may be included in the form of a complex extract including an exosome derived from a bird's nest, a fraction thereof, or a processed product thereof.
  • the composition may contain food additives that can be food physiologically acceptable in addition to the active ingredient.
  • the term "food supplementary additive” refers to a component that can be added auxiliary to food, and is added to the manufacture of health functional foods of each formulation, and can be appropriately selected and used by those skilled in the art.
  • food additives include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, etc. are included, but the types of food additives of the present invention are not limited by the above examples.
  • the food composition of the present invention may contain a health functional food.
  • health functional food refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body.
  • functionality means obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
  • the health functional food of the present invention can be prepared by a method commonly used in the art, and during the production, raw materials and ingredients commonly added in the art may be added to prepare it.
  • the formulation of the health functional food may be prepared without limitation as long as it is a formulation recognized as a health functional food.
  • the food composition of the present invention can be prepared in various forms of formulation, and unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time using food as a raw material, and is excellent in portability.
  • Health functional foods can be consumed as an adjuvant to enhance the effect of improving skin conditions, such as improving skin wrinkles, anti-atopy, anti-inflammatory, whitening, moisturizing, and promoting skin regeneration.
  • the health functional food of the present invention can take, and may include all foods in a conventional sense, and may be mixed with terms known in the art such as functional foods.
  • the health functional food of the present invention can be prepared by mixing appropriate other auxiliary ingredients and known additives that may be included in the food according to the choice of a person skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes and the like, and can be prepared by adding to juice, tea, jelly, juice, etc. prepared using the compound represented by Formula 1 according to the present invention as a main component. It also includes foods used as feed for animals.
  • the present invention provides a composition for improving skin condition, comprising an exosome derived from a bird's nest as an active ingredient.
  • composition for improving skin condition of the present invention has an effect on skin wrinkles by inhibiting the expression of MMP-1 protein, and has an excellent effect in improving atopic dermatitis through inhibition of the expression of Thymus and activation-regulated chemokine (TAC) gene.
  • TAC activation-regulated chemokine
  • composition of the present invention exhibits excellent anti-inflammatory activity by effectively inhibiting the production of nitric oxide, which is an inflammatory mediator, and has excellent moisturizing effect by promoting the synthesis of hyaluronic acid. It suppresses skin whitening activity and has excellent effect on skin regeneration, so it can be usefully used for the purpose of improving skin conditions in the fields of cosmetics, foods, and pharmaceuticals.
  • 1 is an electron micrograph of an exosome derived from a bird's nest.
  • Figure 2 is a graph showing the measurement of the marker proteins of CD9, CD63, and CD81 contained in the exosome (exosome) derived from the nest.
  • Figure 3 is a graph showing the measurement of the expression change of the MMP-1 protein according to the treatment of the exosome (exosome) derived from the nest.
  • FIG. 4 is a graph showing changes in cell viability of a skin keratin cell line according to treatment of an exosome derived from a bird's nest.
  • FIG. 5 is a graph showing changes in the expression of thymus and activation-regulated chemokine (TAC), a specific factor for atopic dermatitis, according to the treatment of exosomes derived from the nest.
  • TAC activation-regulated chemokine
  • FIG. 6 is a graph showing changes in the amount of nitric oxide produced according to the treatment of exosomes derived from bird nest in RAW 264.7 cells, which is a macrophage cell line.
  • FIG. 7 is a graph showing changes in the amount of hyaluronic acid produced according to the treatment of an exosome derived from a bird's nest.
  • FIG. 9 is a graph showing the degree of skin regeneration measured using the Diff quic stain method according to the treatment of exosomes derived from the bird's nest compared to normal cells and quantified.
  • the dissolved solution was put in a 2 mL collection tube, loaded into a filter cartridge, and centrifuged for 2 minutes at 18,000 G.
  • the down layer was transferred to a 1.5 mL microfuge tube, taking care not to fall off the pellets of the centrifuged tube.
  • exosome separation solution was added to the microtube in a volume of 2 times, incubated at 4°C for 48 hours to increase exosome yield, and then centrifuged at 10,000G for 60 minutes. The supernatant was removed from the centrifuged tube to separate the exosome components derived from the nest of seabirds in the form of pellets.
  • the exosome pellet was redissolved in EXO-BB buffer using a sonicator, and then stored at 4° C. and used in subsequent experiments.
  • exosome components derived from the bird's nest isolated in Example 1 were analyzed using a transmission electron microscope (JEM1010, JEOL, Japan) and Dynamic light scattering (DLS) (JEM1010, JEOL, Japan).
  • JEM1010, JEOL, Japan transmission electron microscope
  • DLS Dynamic light scattering
  • Example 2 the exosomes derived from sea swallow nest prepared in Example 1 contained significantly more exosome markers compared to centella, green tea, and ginseng extracts (samples 1 to 3), thereby improving conventional skin conditions.
  • the sea bird's nest which is the raw material of the present invention, contained significantly more exosome components (see FIG. 2).
  • DMEM culture solution 2 ml of DMEM culture solution was added to a 40 mm cell culture dish, and human fibroblasts were inoculated at a concentration of about 1.2 ⁇ 10 5 , and then cultured for 24 hours in an environment of 37° C. and 5% CO 2. Thereafter, the exosomes derived from sea swallow nest prepared in Example 1 were replaced with a medium containing samples diluted to 0.01, 0.1, and 1% (v/v) concentration, and cultured for 3 days. Thereafter, the culture solution was harvested, centrifuged for 5 minutes in an environment at 4°C and 7500 rpm, and then MMP-1 (Human Total MMP-1 kit, R&D Systems, Inc., Minneapolis, MN, USA) using an ELISA method. It was confirmed the change in the protein expression level (see Fig. 3).
  • MMP-1 Human Total MMP-1 kit, R&D Systems, Inc., Minneapolis, MN, USA
  • the negative control group (vehicle) was used at a concentration of 1% (v/v) EXO-BB buffer solution, and the positive control group was used at a concentration of TGF- ⁇ 10 ng/ml.
  • the expression of the MMP-1 protein was decreased in a concentration-dependent manner by the treatment of exosomes derived from the nest, and it was confirmed that the expression of the MMP-1 protein was significantly decreased compared to the negative control group in all treatment sections.
  • the group treated with 1% (v/v) concentration of exosomes derived from the bird's nest showed the same effect as the control group treated with TGF- ⁇ at a concentration of 10 ng/ml as a positive control.
  • the exosomes derived from the bird's nest of the present invention can be effectively used to prevent and improve skin wrinkles by effectively inhibiting the production of MMP-1 protein, which causes wrinkles.
  • Example 4 Atopic improvement: reduction in the expression of atopic dermatitis-specific factor TARC
  • Skin keratin cell line (HaCaT, 5 ⁇ 10 5 /well) was cultured in FBS DMEM medium for 24 hours, and then the exosomes derived from bird's nest were 0.1%, 1%, and 10% (v/v) concentrations in DMEM without FBS. Each was diluted with TNF-a and IFN-r (10 ng/mL), treated simultaneously, and further cultured. After 24 hours, the supernatant of each well was quantified using a human TARC ELISA kit. The group treated with the same amount of distilled water was used as the negative control group, and the group treated with tacrolimus was used as the positive control group.
  • the tacrolimus is an inhibitor of calcineurin and is known to inhibit phosphatase activity inherent in calcineurin (Sieber, M., Karanik, M., Brandt, C., Blex, C., et al., 2007, Inhibition of calcineurin NFAT signaling by the pyrazolopyrimidine compound NCI3., European Journal of Immunology, 37, 2617-2626). Studies have been shown to be effective (Russell, JJ, 2002, Topical tacrolimus: a new therapy for atopic dermatitis. American Family Physician, 66, 1899-1902).
  • the exosome component derived from the bird's nest of the present invention can prevent and effectively improve atopic dermatitis by inhibiting the expression of TARC (thymus and activation-regulated chemokine), which is a specific factor for atopic dermatitis. I could confirm.
  • TARC thymus and activation-regulated chemokine
  • Example 5 Improvement of skin inflammation: inhibition of nitric oxide production
  • nitric oxide which is a representative cytotoxic substance involved in inducing inflammation
  • RAW 264.7 cells a macrophage cell line
  • KTCC Korea Cell Line Bank
  • FBS Fetal bovine serum
  • the RAW 264.7 cells were inoculated into a 96-well plate at a concentration of 1 ⁇ 10 6 cells/mL (in DMEM) and cultured for 24 hours, and then 0.01, 0.1, and 1% of exosomes derived from the nest of the present invention
  • a sample diluted to a concentration of (v/v) and a new medium containing LPS (1 ⁇ g/ml) known as endotoxin were simultaneously treated and cultured for 24 hours.
  • the exosomes derived from the bird's nest of the present invention suppress the production of nitric oxide in all treatment groups compared to the LPS treatment control group (Nor), thereby showing an excellent anti-inflammatory effect.
  • the production of nitrogen oxide decreased by 44% and 58%, respectively, compared to the positive control group treated with Dexamethasone 10uM, indicating that the anti-inflammatory effect was excellent. there was.
  • Example 6 Skin moisturizing: increased hyaluronic acid synthesis
  • Hyaluronic acid (HA, Hyaluronan, Hyaluronic acid) is mainly synthesized by epidermal keratinocytes and dermal fibroblasts, and is a substance that plays an important role in creating an environment in which cells can function normally by binding with water.
  • the decrease in hyaluronic acid in the skin is one of the direct causes of the decrease in skin elasticity and moisture content. Therefore, in this example, the amount of hyaluronic acid produced in human keratinocytes was confirmed.
  • human keratinocytes were inoculated with 1 ml of culture solution in a 24 well cell culture dish, and the cells were inoculated at a concentration of about 1 ⁇ 10 5 , and then cultured for 24 hours at 37° C. and 5% CO 2 Thereafter, the exosomes derived from the nest of sea swallows of the present invention were replaced with a medium containing 0.01, 0.1 and 1% (v/v) concentrations, respectively, and cultured for 24 hours.
  • Hyaluronan kit (Hyaluronan kit, R&D Systems, Inc., Minneapolis, MN, USA) was synthesized using an ELISA method.
  • the group treated with the same amount of distilled water was used as the negative control group, and the group treated with 1 ⁇ M concentration of retinoic acid was used as the positive control group.
  • the hyaluronic acid synthesis increased by 138%, 163%, and 250%, respectively, in the exosome-treated group derived from the bird's nest of the present invention compared to the negative control group (see FIG. 7 ).
  • the exosomes derived from sea swallow nest of the present invention effectively increase the production of hyaluronic acid in skin cells, and can be very effectively used for applications related to skin moisturization.
  • the melanin content was measured by modifying the method reported in the preceding literature (Hosoi et al., 1985). First, the melan-A cells were treated with the exosomes derived from the bird's nest at a concentration of 0.01, 0.1, and 1% (v/v), respectively, for 3 days, and then the medium was removed, and then put into PBS (phosphate buffer saline). Washed twice. Thereafter, in order to dissolve melanin, 400 ⁇ l of 1N NaOH was added, and the melanin content was measured at an absorption wavelength of 405 nm using a microplate reader. The group treated with the same amount of distilled water was used as the negative control group, and the group treated with the 10 ⁇ M concentration of arbutin was used as the positive control group.
  • PBS phosphate buffer saline
  • the exosomes derived from the bird's nest of the present invention can be effectively used for skin whitening-related purposes by effectively inhibiting the production of melanin in skin cells.
  • Cell proliferation was measured using a methylthiazole-2-yl-2.5-diphenyl tetrazolium bromide (MTT) analysis method and a diff quic stain method, and then confirmed with a microscope and quantified compared to normal cells. Shown in.
  • MTT methylthiazole-2-yl-2.5-diphenyl tetrazolium bromide
  • the exosome component derived from the nest of sea swallows of the present invention when applied to damaged skin, the regenerated skin tissue does not differ from the surrounding normal skin tissue. It was found that it has the effect of promoting the regeneration of skin cells while preventing it from appearing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition antibactérienne et antifongique comprenant un extrait de clou de girofle, d'hibiscus et de noix de coco comme principe actif. L'extrait combiné de clou de girofle, d'hibiscus, et de noix de coco selon la présente invention présente une excellente activité antibactérienne et antifongique en exerçant une influence directe sur des microbes nuisibles tout en ayant des effets, telles que la réduction des rides cutanées, l'atténuation de l'inflammation dermique, l'antioxydation, etc. L'extrait peut donc être avantageusement utilisé dans une composition pharmaceutique, une composition cosmétique, un conservateur pour la conservation d'aliments ou d'aliments pour animaux, etc.
PCT/KR2019/015996 2019-10-04 2019-11-21 Composition comprenant un exosome dérivé de nid d'océanite à queue fourchue en tant que principe actif pour améliorer une condition cutanée WO2021066248A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0122940 2019-10-04
KR1020190122940A KR102159394B1 (ko) 2019-10-04 2019-10-04 바다제비집에서 유래된 엑소좀을 유효성분으로 포함하는 피부 상태 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2021066248A1 true WO2021066248A1 (fr) 2021-04-08

Family

ID=72706584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/015996 WO2021066248A1 (fr) 2019-10-04 2019-11-21 Composition comprenant un exosome dérivé de nid d'océanite à queue fourchue en tant que principe actif pour améliorer une condition cutanée

Country Status (2)

Country Link
KR (1) KR102159394B1 (fr)
WO (1) WO2021066248A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102503542B1 (ko) * 2022-06-17 2023-02-24 한국콜마주식회사 오레가노 추출물 및 병풀 유래 엑소좀의 혼합물을 포함하는 피부 개선용 조성물
KR102540485B1 (ko) 2022-10-25 2023-06-08 (주)지에프씨생명과학 에델바이스, 사막장미, 병풀 또는 하수오 유래 엑소좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물
KR102564765B1 (ko) 2022-10-25 2023-08-09 (주)지에프씨생명과학 라벤다, 어성초 또는 티트리 유래 엑소좀을 유효성분으로 포함하는 항염 및 피부 진정용 화장료 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101257381B1 (ko) * 2010-04-20 2013-04-23 스킨큐어(주) 제비집추출물을 유효성분으로 포함하는 피부 상태개선용 조성물
US20150023908A1 (en) * 2011-03-04 2015-01-22 Ahmed H. Al-Qahtani Skin cream
KR101580107B1 (ko) * 2015-06-09 2015-12-28 (주)더마랩 버섯균사체 발효 제비집 추출물을 유효성분으로 함유하는 화장료 조성물
KR20160123619A (ko) * 2015-04-16 2016-10-26 남상범 바다제비집 추출물을 유효성분으로 포함하는 기능성 화장료 조성물
KR20180086062A (ko) * 2017-01-20 2018-07-30 (주)에스디생명공학 바다제비집 복합 추출물을 유효성분으로 함유하는 여드름 피부의 피부 상태 개선용 조성물
KR101963572B1 (ko) * 2017-04-11 2019-03-29 코스맥스 주식회사 아스페르길루스 크리스타투스 균주로 발효시킨 발효 제비집의 추출물을 포함하는 피부미용 개선용 조성물
KR20190060672A (ko) * 2017-11-24 2019-06-03 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101769422B1 (ko) * 2016-02-25 2017-08-18 원광보건대학교 산학협력단 다중기능성 세럼형 화장품의 혼합 조성물 및 제조방법
KR101860266B1 (ko) * 2016-07-01 2018-05-24 사회복지법인 삼성생명공익재단 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101257381B1 (ko) * 2010-04-20 2013-04-23 스킨큐어(주) 제비집추출물을 유효성분으로 포함하는 피부 상태개선용 조성물
US20150023908A1 (en) * 2011-03-04 2015-01-22 Ahmed H. Al-Qahtani Skin cream
KR20160123619A (ko) * 2015-04-16 2016-10-26 남상범 바다제비집 추출물을 유효성분으로 포함하는 기능성 화장료 조성물
KR101580107B1 (ko) * 2015-06-09 2015-12-28 (주)더마랩 버섯균사체 발효 제비집 추출물을 유효성분으로 함유하는 화장료 조성물
KR20180086062A (ko) * 2017-01-20 2018-07-30 (주)에스디생명공학 바다제비집 복합 추출물을 유효성분으로 함유하는 여드름 피부의 피부 상태 개선용 조성물
KR101963572B1 (ko) * 2017-04-11 2019-03-29 코스맥스 주식회사 아스페르길루스 크리스타투스 균주로 발효시킨 발효 제비집의 추출물을 포함하는 피부미용 개선용 조성물
KR20190060672A (ko) * 2017-11-24 2019-06-03 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도

Also Published As

Publication number Publication date
KR102159394B1 (ko) 2020-09-24

Similar Documents

Publication Publication Date Title
WO2021066248A1 (fr) Composition comprenant un exosome dérivé de nid d'océanite à queue fourchue en tant que principe actif pour améliorer une condition cutanée
WO2017052155A1 (fr) Composition pour le blanchiment de la peau contenant du bêta-mangostin comme principe actif
KR20120138089A (ko) 멍게껍질 추출물을 유효성분으로 포함하는 탈모 방지, 발모 촉진 및 두피 개선용 조성물
TWI747280B (zh) 余甘子萃取發酵物及其製備與應用
JP2004067590A (ja) 女性ホルモン産生促進剤及びこれを含有する皮膚外用剤
KR20210056984A (ko) 피부 개선용 조성물
KR101440675B1 (ko) 홍삼 오일을 유효성분으로 함유하는 피부 주름 개선용 조성물
KR20210018388A (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR101705354B1 (ko) 고사리삼 알코올 추출물을 포함하는 피부 염증 예방 또는 치료용 조성물
KR102209663B1 (ko) 조팝나무 추출물을 포함하는 피부질환 예방 또는 치료용 조성물
KR20180040756A (ko) 율무 추출물을 포함하는 미백용 조성물
KR101430636B1 (ko) 진세노사이드 Ｒｈ2 및 진세노사이드 Ｒｇ3를 함유하는 기능성 화장료 조성물
WO2015034247A1 (fr) Composition contenant un composé de monoacétyldiacylglycérol comme principe actif pour prévenir ou traiter la dermatite atopique
KR102386120B1 (ko) 밀크씨슬 꽃 추출물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR20190018108A (ko) 티몰을 유효성분으로 함유하는 피부 주름 또는 아토피성 피부염의 예방 또는 치료용 조성물
RU2689321C2 (ru) Композиции и способы ингибирования синтеза триглицеридов с помощью синергетической комбинации ботанических составов
KR20140089305A (ko) 참가시나무 추출물를 활성성분으로서 포함하는 피부 미백 또는 주름개선용 조성물
KR101599458B1 (ko) 백기생 알코올 추출물을 포함하는 피부 염증 예방 또는 치료용 조성물
KR101906896B1 (ko) 티몰 및 미르센을 유효성분으로 함유하는 아토피성 피부염의 예방 또는 치료용 조성물
TWI706792B (zh) 臭菘提取物或其餾分的用途
KR101541470B1 (ko) 진세노사이드 ｆ2를 포함하는 탈모방지 또는 발모촉진용 조성물
KR20120131064A (ko) 아위느타리버섯으로부터 분리된 신규한 엘라스타제 저해제 및 이를 유효성분으로 함유하는 노화 예방 또는 개선용 조성물
KR20170025352A (ko) 피부 개선용 조성물
KR102245188B1 (ko) 피부 개선용 조성물
KR101526435B1 (ko) 머루근 추출물을 포함하는 미백용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19947829

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19947829

Country of ref document: EP

Kind code of ref document: A1